This section highlights FDA-related milestones and regulatory updates for drugs developed by Genmab A/S (GNMSF).
Over the past two years, Genmab A/S has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
Rina-S and epcoritamab. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
Rina-S FDA Regulatory Events
Rina-S is a drug developed by Genmab A/S for the following indication: In Heavily Pretreated Patients with Ovarian and Endometrial Cancers.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- Rina-S
- Announced Date:
- October 23, 2026
- Indication:
- In Heavily Pretreated Patients with Ovarian and Endometrial Cancers
Announcement
Genmab A/S announced positive topline results from the global Phase 3 RAINFOL™-02 trial of rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), in patients with platinum-resistant ovarian cancer (PROC) regardless of FRα expression level or prior treatment with mirvetuximab.
Read Announcement- Drug:
- Rina-S
- Announced Date:
- October 4, 2026
- Indication:
- In Heavily Pretreated Patients with Ovarian and Endometrial Cancers
Announcement
Genmab A/S announced results from Part C of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), demonstrated that among 109 treated patients with platinum-resistant ovarian cancer (PROC), Rina-S achieved a confirmed objective response rate (ORR) of 45.9% (95% CI: 36.3–55.7), including five complete responses (CRs) and a median duration of response (mDOR) of 12.1 months (95% CI: 6.5–15.4), with 51% of responders remaining in response at one year.
AI Summary
Genmab reported positive results from Part C of the Phase 1/2 RAINFOL-01 trial of Rina-S, an investigational cancer drug, in 109 people with platinum-resistant ovarian cancer. At a dose of 120 mg/m² every three weeks, 45.9% of patients had their tumors shrink, including five whose tumors disappeared. The median time patients remained in response was 12.1 months, and 51% of responders were still responding after one year. Median time without cancer worsening was 9.5 months.
Responses occurred across different levels of folate receptor alpha, including low or undetectable levels, and regardless of prior mirvetuximab treatment. More than half the patients had received three or four prior treatment lines. Common side effects included nausea, fatigue, anemia, and low neutrophil counts; 5.5% stopped treatment because of side effects. Genmab said Phase 3 studies of Rina-S are underway or planned. Its safety and effectiveness have not been established.
Read Announcement
Epcoritamab FDA Regulatory Events
Epcoritamab is a drug developed by Genmab A/S for the following indication: To-Treat Relapsed/Refractory Follicular Lymphoma.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- epcoritamab
- Announced Date:
- October 5, 2026
- Indication:
- To-Treat Relapsed/Refractory Follicular Lymphoma
Announcement
Genmab A/S and AbbVie announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of 2 to 5.
AI Summary
Genmab reported positive results from Part C of the Phase 1/2 RAINFOL-01 trial of Rina-S, an investigational cancer drug, in 109 people with platinum-resistant ovarian cancer. At a dose of 120 mg/m² every three weeks, 45.9% of patients had their tumors shrink, including five whose tumors disappeared. The median time patients remained in response was 12.1 months, and 51% of responders were still responding after one year. Median time without cancer worsening was 9.5 months.
Responses occurred across different levels of folate receptor alpha, including low or undetectable levels, and regardless of prior mirvetuximab treatment. More than half the patients had received three or four prior treatment lines. Common side effects included nausea, fatigue, anemia, and low neutrophil counts; 5.5% stopped treatment because of side effects. Genmab said Phase 3 studies of Rina-S are underway or planned. Its safety and effectiveness have not been established.
Read Announcement